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Drug developmentIn eukaryotic cells, the ubiquitin–proteasome-system (UPS) is responsible for the non-lysosomal degradation
of proteins and plays a pivotal role in such vital processes as protein homeostasis, antigen processing or cell
proliferation. Therefore, it is an attractive drug target with various applications in cancer and immunosuppres-
sive therapies. Being an evolutionary well conserved pathway, many pathogenic bacteria have developed
small molecules, which modulate the activity of their hosts' UPS components. Such natural products are,
due to their stepwise optimization over the millennia, highly potent in terms of their binding mechanisms,
their bioavailability and selectivity. Generally, this makes bioactive natural products an ideal starting point
for the development of novel drugs. Since four out of the ten best seller drugs are natural product derivatives,
research in this ﬁeld is still of unfathomable value for the pharmaceutical industry. The currently most prom-
inent example for the successful exploitation of a natural compound in the UPS ﬁeld is carﬁlzomib
(Kyprolis®), which represents the second FDA approved drug targeting the proteasome after the admission
of the blockbuster bortezomib (Velcade®) in 2003. On the other hand side of the spectrum, ONX 0914,
which is derived from the same natural product as carﬁlzomib, has been shown to selectively inhibit the im-
mune response related branch of the pathway. To date, there exists a huge potential of UPS inhibitors with re-
gard to many diseases. Both approved drugs against the proteasome show severe side effects, adaptive
resistances and limited applicability, thus the development of novel compounds with enhanced properties
is a main objective of active research. In this review, we describe the techniques, which can be utilized for
the discovery of novel natural inhibitors, which in particular block the 20S proteasomal activity. In addition,
we will illustrate the successful implementation of a recently published methodology with the example of a
highly potent but so far unexploited group of proteasome inhibitors, the syrbactins, and their biological func-
tions. This article is part of a Special Issue entitled: Ubiquitin–Proteasome System. Guest Editors: Thomas
Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The ubiquitin–proteasome-system (UPS) selectively labels and de-
stroys short-lived, misfolded and abnormal proteins, therefore playing
a crucial role in protein homeostasis [1]. Moreover, it is involved in
important biological pathways and signaling processes via the degrada-
tion of cellular key players such as cyclins [2] or the tumor suppressor
p53 [3]. Besides, not only the digestion of substrates, but also the gener-
ation of peptide fragments is exploited in vertebrates for the generation
of antigens that are presented on MHC-I complexes at the cell surface
[4,5]. Due to the entanglement with these vital processes, the UPS is di-
rectly linked to diseases as diverse as cancer, autoimmunity or
neurodegeneration [6,7], which can in turn be correlated with aberrant
proteasomal activity or increased expression of genes involved in the
UPS [8]. Hence, the pharmaceutical manipulation of the UPS activity istin–Proteasome System. Guest
ichael.groll@tum.de (M. Groll).
l rights reserved.a promising principle for the treatment of various diseases. Despite
the vast potential, the medical application of UPS inhibitors is still lim-
ited to only certain types of blood cancer [9]. Nevertheless, the discov-
ery of various natural substance classes acting on the UPS demonstrates
the tremendous importance of this pathway for biological systems
and raises hopes to also apply similar compounds to a broader spectrum
of medical indications [10]. These secondary metabolites feature dis-
tinct modes of action, carry unique lead structures and fulﬁll a speciﬁc
biological function such as the attenuation of the immune system or
the general debilitation of a host organism [11,12]. In contrast to most
synthetic compounds, they do not only show excellent in vitro effects,
but are also able to selectively mingle with the UPS in living cells [13],
which is largely due to their outstanding properties in terms of cell pen-
etration, clearance rates,metabolism and binding kinetics. Thus, natural
products represent a perfect starting point for further drug develop-
ment. However, not all of them can be used because of their complex
structure or their high reactivity, which potentially causes detrimental
side effects. Therefore, the search for novel compounds remains an im-
portant ﬁeld of future research. Although recent studies demonstrate
that many components of the UPS pathway are equally drugable, the
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(core particle; CP) upon its validation as a cancer drug target. Due to the
diversiﬁcation of the UPS in higher vertebrates, the exploitation of its
different branches emerges as a newprinciple for UPS inhibitors. Conse-
quently, all components of the UPS are of high interest to the pharma-
ceutical industry, especially with regard to other clinical pictures than
multiple myeloma or mantle cell lymphoma for which bortezomib re-
ceived its primary admission [14].
2. Chapter 1: The UPS pathway
2.1. Ubiquitination
The in vivo stability of a given protein in pro- and eukaryotes is
determined by the so called N-end rule [15]. It deﬁnes particular
N-terminal amino acids such as lysine or arginine as degradation sig-
nals that considerably abbreviate the protein's half-life time. In nucle-
ated cells, the UPS is majorly responsible for the substrate selective
digestion of proteins [16,17]. The pathway consists of two parts, the
covalent ubiquitination of target proteins and their successive decom-
position by the 26S proteasome to deﬁned oligopeptides [18] (Fig. 1).
Ubiquitin (Ub) is a comparatively small but vital 8.5 kDa protein that
can be posttranslationally attached to the ε-NH2 moiety of an exposed
lysine residue by an isopeptide bond [23]. Further Ub molecules can
then be coupled to the ﬁrst Ub via any of its seven lysine amino
acids to form differently linked chains with particular signaling func-
tions such as translocation or degradation [24,25]. Due to their high
cellular abundance, K48 linked poly-Ub chains are the best character-
ized type of ubiquitination and have been shown to mark proteins for
proteasomal fragmentation [26]. The overall ubiquitination of the pro-
teome is a highly dynamic process that has been likened in its com-
plexity and cellular function to phosphorylation [27]. It is balanced
and controlled by a system of substrate speciﬁc Ub ligases on the
one hand side and deubiquitinases on the other that represent an en-
tire posttranslational regulation level. The molecular mechanism of
ubiquitination involves three successive enzymes called E1 (ubiquitin
activating enzyme), E2 (ubiquitin conjugating enzyme) and E3
(ubiquitin-protein ligase), which activate, hand over and attach a UbFig. 1. The UPS pathway. A) Ubiquitinylation involves three enzymes, which activate (E1, up
(red) to a cellular substrate protein. B) The 26S proteasome with a molecular mass of 2.600
gray), which is ﬂanked by two 19S RP's (gray); coordinates were provided by Edward Morr
(black). Diversiﬁcation of the UPS in vertebrates has led to three distinct particles with a
color-coded for the each CP type: iCP (green), cCP (red) and tCP (β1i and β2i in green; β5tmoiety to a target protein [25] (Fig. 1a). These enzymes are arranged
in a cascade like reaction setup, starting with two E1 enzymes that in-
teract with about ﬁfty E2 proteins [28]. The E2:Ub complexes are then
able to speciﬁcally select their target E3 ligase amongmore than 1000
E3enzymes [28,29], hereby reﬂecting the enormous variety of proteins
that are posttranslationally labeled for disposal. Hereby, Ub gets
ATP-dependently activated by its C-terminal carboxyl-group via E1
to yield a highly energetic Ub–E1 thioester bridged metabolite [30],
which in turn transmits the Ub moiety to an E2 protein [30,31]. Suit-
able UPS substrate proteins are either recognized by E3 alone or in a
trimeric complexwith E2, which then provides the activated ubiquitin
for the catalyzed ligation to the substrate [32]. Once ubiquitinated, re-
peated cycles of these steps lead to attachment of further Ub moieties
to the ﬁrst Ubmolecule [33], thus resulting in proteins with isopeptide
bridged oligo-Ub chains that are recognized and degraded by the 26S
proteasome.
2.2. The 26S proteasome
Once a substrate molecule is successfully polyubiquitinated, it is
caught by the 26S proteasome (Fig. 1b). This 2.6 MDa huge multimeric
particle is composed of the proteolytically active 20S proteasome (core
particle, CP) and the 19S regulatory particle (RP) [18]. The RP recognizes
ubiquitinated substrate proteins, unfolds them in an ATP dependent
manner and translocates them into the CP. Although the dynamic and
ﬂexible structure of the RP has thwarted attempts of crystal structure
analysis to date, recent electron microscopy studies have shed new
light on its functional and molecular organization [22,34]. In a cap-like
structure, the RP is perched on both ends of the barrel shaped CP, thus
gating entry for substrate molecules into the catalytic sites [35–39]
(Fig. 1b). Its 19 different proteins are categorized into Rpt (Regulatory
particle ATPases) as well as Rpn subunits (Regulatory particle non-
ATPases) and were historically further subdivided into two multimeric
complexes called “base” and “lid” according to their presumed location
within the RP [40]. Computational, structural and biochemical studies,
however, havemade these categories superﬂuous as the lid is not locat-
ed on top of the RP but rather on its side [34]. Moreover, subunits that
had been assigned to the base such as Rpn 10 and Rpn 13 [34,40] thatper) [19], hand over (E2, middle) [20] and conjugate (E3, lower) [21] the Ub molecule
kDa is huge compared to the 8.5 kDa Ub molecule. It contains the proteolytic CP (light
is [22]. In eukaryotes, only three β-type subunits are endowed with catalytic activities
ltered β-subunit conﬁguration. The proteolytically active subunits β1, β2 and β5 are
in blue).
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of the RP [22,34]. These two proteins are the primer receptors to recog-
nize tetra-Ub chains. Once bound to the RP, the labeled substrates are
guided to the catalytically active zink-metallaprotease Rpn11 [44] that
is located in the palm of the horseshoe like setup formed by the
residual subunits Rpn 3, 5–7, 9 and 12 [45]. Rpn11 then cleaves off
the prearranged Ub molecules en bloc, thus rescuing them from
proteasomal degradation. Subsequently, the substrate protein gets
(i) actively unfolded by the six AAA+ ATPases (Rpt 1–6) [46–50],
which are located in a pseudohexameric spiral staircase arrangement
adjacent to the CP [22,34] and (ii) is further translocated into the hydro-
lytic chamber of the 20S proteasome [38,39].
2.3. The core particle
Contrary to the dynamic RP, the CP is a rigid body framed by the RP
[17] or other adaptor proteins [51–53] (Fig. 1b). It forms the down-
stream end of the UPS and exerts the catalytic activity that cleaves pro-
teins into deﬁned peptide fragments [54,55]. Unlike for the RP, high
resolution data is available for the 20S proteasomes from prokaryotes
[56] and eukaryotes [35,57,58]. This allowed the elucidation of its mo-
lecular structure, including the details of substrate binding and conver-
sion, as well as extensive studies with inhibitory molecules [59]. The C2
symmetrical CP cylinder is composed of four stacked heptameric rings
containing α- and β- subunits in an α1-7β1-7β1-7α1-7 stoichiometry
[56]. The outer α subunits actively participate in CP assembly and play
scaffolding and functional roles in the maturated particle. By spanning
an interdigitating network with their N-termini, the α-subunits form
a gate and actively lock the central proteasomal pore, thus protecting
the cell from uncontrolled self-digestion by free 20S particles [35–37].
Once the RP is docked on theα-subunits, however, this regulatory func-
tion is passed on to the ubiquitin related branch of the UPS and the gate
is opened by a distinct interaction with the Rpt-proteins [39,60]. The
proteolytic activities of the CP that in turn degrade an introduced un-
folded protein are conferred to subunits within the equatorial β-rings
[61]. During the catalytic reaction, the nucleophilic Thr-1Oγ attacks
the carbonyl carbon of the scissile peptide bond, thereby forming a sta-
bilized oxyanion [35,62]. Next, the C-terminal substrate fragment is re-
leased, which results in a peptide–enzyme–acyl intermediate that is
subsequently attacked by a prearranged water molecule in the Bürgi–
Dunitz trajectory to complete peptide bond hydrolysis [63,64]. With re-
gard to thismechanism including the role of the free N-terminus as pro-
ton acceptor, the CP is assigned to the family of Ntn (N-terminal
nucleophilic) hydrolases [65]. As the proteolytic machinery is entirely
unspeciﬁc, the CP can be compared to a molecular shredder that has
to be strictly compartmented in vivo [18]. However, although it is not
selective with respect to the digested protein, it is endowedwith cleav-
age speciﬁcity by its peptide binding channels [59]. These harbor dis-
tinct pockets for the amino acid side chains of substrate molecules,
thereby prolonging the mean residence time of peptides with suitable
primary sequences [35]. In turn, proteins are preferentially hydrolyzed
at deﬁned positions, eventually resulting in a reproducible cleavage
pattern with respect to a deﬁned substrate [54,55]. Interestingly,
whereasmost simpler organisms such as archaea get alongwith identi-
cal α- and β-subunits [56], eukaryotes harbor distinct subunits with
only three catalytically active β-type subunits that are named β1, β2
and β5 according to their position within the seven-membered rings
[35] (Fig. 1b). Due to their distinct substrate speciﬁcities, the activities
exerted by these subunits are termed caspase-like (CL), trypsin-like
(TL) and chymotrypsin-like (ChTL) [61,66].
This divergent evolution of subunits present in eukaryotes conduces
to the functional diversiﬁcation of the UPS and its involvement in
intracellular signaling [2,3,67]. Moreover, in vertebrates, the active
β-subunits have further evolved to several subsets with particular sub-
strate selectivities [6,66]. Due to their assigned function or the tissue in
which they are produced, they are incorporated into nascent CP's, whichare consequently named constitutive (cCP), immuno (iCP) or thymus
core particles (tCP) [68,69] (Fig. 1b). This further specialization enables
a deﬁned participation of the CP in the various biological pathways in-
herent in higher organisms. In 2012, the crystal structure of the murine
iCP, aswell as the corresponding cCP,were elucidated [58]. Comparative
analysis of the exchanged subunits revealed, that the overall folding of
the immuno- and constitutive subunits matches almost perfectly. The
molecular details for the altered catalytic properties were disclosed,
hereby opening the opportunity for the rational design of cCP or iCP se-
lective inhibitors. Interestingly, the β2c and β2i subunits both preferen-
tially cleave after basic residues and exhibit a broad range of substrate
speciﬁcity. Thus, the functional and biological background of this re-
placement still remains elusive to date [6]. Contrarily, the substrate se-
lectivity of β1i is changed from acidic (CL) towards small branched
amino acids, which are better suited to bind to MHC I complexes
[58,70]. Although the thymoproteasome is linked to various autoim-
mune diseases, little is known about the cleavage preferences of the
β5t subunit [71]. Structural predictions and initial experiments, howev-
er, suggest that its peptide binding channel is lined by hydrophilic resi-
dues [68]. Therefore, the production of peptides with hydrophobic
residues is attenuated in β5t, thus afﬁnity of these ligands forMHCI pre-
sentation is limited. As T-cell development is impaired in β5t knockout
mice, the thymus speciﬁc subunit has been connected to positive CD8+
T-cell selection [68]. In contrast, the cleavage preference of β5c towards
small neutral amino acids has been shown to be altered in β5i to large
hydrophobic residues, which enhances antigen presentation [58].
Therefore, β1i and β5i exhibit a converged and directed evolution
towards a concerted production of antigenic peptides, thus generat-
ing a broader spectrum of possible epitopes most suitable for MHC I
binding [70]. The further adaptation and specialization of the CP in
different cell types reﬂects the increased complexity in higher eu-
karyotic organisms and might offer a chance to selectively address
different pathways by medicinal chemistry [6]. Today, the CP is in
the focus of the pharmaceutical industry within the UPS. This is due
to its far downstream position and straightforward addressable enzy-
matic activity, but also to its signaling function in cell proliferation,
immune response and inﬂammatory processes such as the NF-κB
pathway [6,72]. For the same reasons, the CP is also exploited by
pathogenic microorganisms via small molecules during infection.2.4. Natural and synthetic CP inhibitors and their potential applications
To date, many entirely different classes of natural CP inhibitors have
been described [10] (Fig. 2). They all display distinct modes of action
and selectively block proteasomal β-subunits to address the various
proteasomal functions [59,83]. After the discovery of the rather
unspeciﬁc peptide aldehydes [56,66], the β-lactone omuralide was
among the ﬁrst natural proteasome inhibitors identiﬁed [74,84]
(Fig. 2a–b). Lactones belong to the original antibiotic agents discovered
and consequently this class of natural products represents the model
compound in the ﬁeld of small molecule CP inhibitors [35,64,85].
Upon CP binding, the strained β-lactone ring in omuralide undergoes
a nucleophilic ring opening reaction with Thr-1Oγ to form an irrevers-
ible acyl–enzyme product [35] (Fig. 2b), thus blocking the proteasomal
active sites. It was shown that omuralide is quite speciﬁc for the
proteasome and selectively blocks the ChTL activity [35,84]. Moreover,
treatment with the natural metabolite causes cell cycle arrest and
neurite outgrowth in cell culture experiments by inhibition of cyclin
degradation [84], therefore assigning a deﬁned biological mode of
action. As tumor cells exhibit high protein turnover rates in combination
with chromosomal instability and abbreviated cell division intervals
[86], CP inhibitors stepped into the limelight of cancer therapy.
Although the pharmaceutical exploitation of omuralide was abandoned
due to its high off-target activities, a closely related natural compound
named Marizomib (Fig. 2d) is currently under clinical trials [87].
Fig. 2. Natural product inhibitors of the proteasome. a) The peptide aldehyde Fellutamide B and b) the β-lactone omuralide belong to the ﬁrst natural proteasome inhibitors identiﬁed
[73,74]. c) Belactosin C [75] and d) salinosporamide A (marizomib) [76] join the class of β-lactones, whereby the hydroxyl moiety of the latter reacts in a second step to produce an
irreversible tetrahydrofuran ether. e) Epoxomicin carries a bifunctional α’, β’-expoxyketone pharmacophore [77]. The newly released carﬁlzomib as well as ONX 0914 are derived
from this natural compound. f) Carmaphycin A is another member of this highly potent inhibitor class that combines the reactive pharmacophore with a distant lipophilic tail
[78]. g) TMC-95A is the only natural non-covalent CP inhibitor identiﬁed to date [79]. Its biaryl-bridged (oxindol–phenyl clamp) peptide scaffold carries many decorations and chiral
centers that shape the compounds' three-dimensional structure, thus balancing the enthalpic loss by enhanced entropic properties. h) Syringolin A, as well as i) glidobactin A and
j) cepafungin I belong to the class of syrbactins [80–82]. They all harbor a constrained Michael-system in a twelve-membered macrolactam ring attached to either a carboxylic
acid or a fatty acid tail, respectively. CepI is the most powerful natural inhibitor identiﬁed to date. Only those compounds are displayed for which crystallographic data are available.
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thetic blockbuster drug bortezomib, which is approved for relapsed mul-
tiple myeloma and mantle cell lymphoma [88–90]. The boronic acid
pharmacophore of the peptide inhibitor binds to the nucleophilic
Thr-1Oγ to form a covalent tetrahedral adduct that mimics the oxyanion
during peptide cleavage [91]. The prescriptive application of bortezomib
as a line-one drug against multiple myeloma has validated the CP within
the UPS as a promising target for cancer therapy [9]. Besides, laboratory
experiments have demonstrated reduced rejection rates in transplanted
and bortezomib treated mice, thereby highlighting the clinical impor-
tance of the immunological role of the CP including autoimmune disor-
ders [92,93]. On the other hand, the application of bortezomib suffers
from severe side effects like peripheral neuropathy or myelotoxicity as
well as limited tissue penetration and short bioavailability [94–96]. All
these effects are assigned to the extremely reactive boronic acidwarhead,
which causes substantial off-target activities [97]. It is therefore currently
of central interest to develop equally potent compounds with reduced
cross reactivity and improved pharmacokinetic properties. The admission
of carﬁlzomib in 2012 [98], which is based on the highly potent natural
product epoxomicin from an Actinemyces strain [77,99,100] (Fig. 2e),
now heralds the era of second generation proteasome inhibitors. The bi-
valent and irreversible α′,β′-epoxyketone compound reacts with the
hydroxyl- and with the amine moiety of Thr-1 [101], which considerably
contributes to target speciﬁcity towards only those few members of the
Ntn-hydrolase family [10] (Fig. 2e–f). In clinical studies, carﬁlzomib sports
high potency in treatment of multiple and refractory multiple myelomawith response rates of 52% in single-arm phase II studies [102], whereas
complimentary applications with other established compounds such as
the thalidomide derivative lenalidomide or the glucocorticoid dexameth-
asone even yielded rates of 92% [103]. Due to the orthogonal toxicological
side effects of these substances, treatment could be performed over
several years without dose reduction [103]. Another derivative of
epoxomicin, which is currently in medicinal research focus, is the
ﬁrst-in-class immunoproteasome inhibitor ONX 0914 [104]. The com-
pound holds promising applications in various autoimmune diseases,
transplantation therapy as well as treatment of several cancer subtypes
with abnormal iCP expression patterns [6,105]. Currently, ONX 0914
is tested in preclinical studies for treatment of immune disorders.
However, both carﬁlzomib and ONX 0914 still resemble bortezomib in
their highly reactive pharmacophore, which complicates their application
inmedical treatment e.g. due to premature hydrolysis in the bloodplasma
[106].
2.5. Substrate toxication of the CP by cyclic peptides
In contrast to bortezomib and carﬁlzomib, the cyclic peptide
TMC-95A, which was isolated from cultures of Apiospora montagnei
[79,107] (Fig. 2g), belongs to the class of reversible and non-covalent in-
hibitors [108]. However, with an IC50 of 5 nM its inhibitory strength is in
the same order as covalently reacting substances, thus demonstrating
that binding afﬁnity is dependent on both enthalpy and entropy
[109,110]. Since reversible inhibitors only temporarily block the
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[83,111]. Moreover, they are hypothesized to penetrate further into
the tissue due to the dynamic equilibrium of their binding, thusmaking
TMC-95A an interesting candidate for pharmaceutical research. Howev-
er, attempts to synthesize TMC-95A did not lead to satisfactory results
due to its demanding stereochemistry [110,112–115]. Therefore, the
complex structure was reduced to the crucial functional determinants,
however none of the derivedmolecules reached the inhibitory potential
of TMC-95A [109,116,117]. Moreover, the search for other non-covalent
inhibitors did not lead to the discovery of new compounds. Major rea-
sons therefore are the dominance of irreversible inhibitors, but also to
the lack of appropriate assay techniques for CP activity evaluation.
2.6. Proteasomal inhibitors from pathogenic sources trigger virulence
Eventually, the syrbactin compounds, which are named after their
most prominent examples syringolin A (SylA), glidobactin A (GlbA) and
cepafungin I (CepI) represent the latest group of natural CP inhibitors
identiﬁed to date [11,12,81,118,119] (Fig. 2h–j). They share the common
feature of an 18-membered macrolactam scaffold containing a
Michael-system as electrophilic group that reacts with the Thr-1Oγ to
produce an irreversible ether product [12]. Interestingly, analog synthetic
compounds such as vinyl esters or vinyl sulfones exhibit the same reac-
tion mechanism [120–123]. Yet, their IC50 values range in the
micromolar range, whereas the syrbactins reach nanomolar values
[11,124]. Comparative structural studies suggest that the rather
unreactive Michael-system has to be prepositioned to unfold its true po-
tential, which is achieved in the syrbactin family by the restrained
macrolactam scaffold [13,125,126]. Furthermore, binding is entropically
favored towards elongated andﬂexible peptide chains,which lose consid-
erable degrees of freedom compared to their state in free solution. Fur-
thermore, the intracyclic carbonyl oxygen simulates the oxyanion in
substrate digestion and is therefore stabilized by hydrogen bonds with
Gly-47NH [124]. Due to the hydrophobic character of the macrolactam
ring, all syrbactins preferentially bind to the β5 subunit. However, the
decoration pattern between SylA and GlbA differs considerably in the S1
site, as well as the acyl-chain attached to the cyclic system [13,80,81].
These alterations account for the tremendously improved IC50 values of
glidobactin compared to syringolin. Whereas the isopropyl moiety of
syringolin is spatially demanding for the cCP, thereby shifting Met-45
out of its native state, the methyl group in glidobactin perfectly ﬁts into
the P1 pocket [11,12]. Besides, binding of the P3 threonine next to the
mactolactam ring is improved due to characteristic hydrogen bond for-
mations. More importantly, however, is the exchange of the very polar
free carbonic acid tail of SylA by a partially unsaturated fatty acid chain
in GlbA, which was shown to bind into a hydrophobic grove in the adja-
cent proteasomal subunit β6 [12]. Remarkably, the highly potent GlbA
with an IC50 value of 17 nMwas still improved during evolutionary opti-
mization, which resulted in CepI [11,82] (Fig. 2j). Recent results elucidat-
ed that CepI, which exhibits an IC50 value of 4 nM, currently represents
one of the strongest proteasomal inhibitor described so far. X-ray struc-
ture elucidation of the yeast CP in complexwith CepI revealed themolec-
ular details of its enhanced binding properties, which are assigned to the
increasedhydrophobic interactions of the branched fatty acid tailwith the
respective lipophilic proteasomal grove [11]. Therefore, SylA, GlbA and
CepI follow a commonmode of action, but differ from each other by a di-
rected optimization of individual side chains withmajor impacts on their
respective binding afﬁnities (Fig. 2h–j).
Contrary to most covalent inhibitors characterized to date, the
syrbactins carry a rather unreactive electrophilic headgroup, thus
suggesting decreased cross reactivity and adverse side effects. Hence,
the syrbactins are likely to follow carﬁlzomib and marizomib [98] as sec-
ond generation CP inhibitors in the future. The high versatility of the cur-
rently identiﬁed CP-ligands gives a ﬁrst insight into the vast repertoire
that nature has developed to interactwith theUPS by smallmolecule elic-
itors [10]. Therefore, many other hitherto undescribed compounds arestill waiting for their discovery to join the ﬁeld of natural proteasome in-
hibitors. Considering the unexploited applications of UPS modulating
agents in cancer therapies and also the recently disclosed area of selective
iCP and tCP inhibition [6], the search for novel lead structures is of utmost
importance for both academia and industry.
Unfortunately, natural product research in our days is in a severe di-
lemma. The number of newly identiﬁed substances is steadily declining,
whereas at the same time the effort for their discovery surpasses econom-
ic efﬁciency criteria, which has led to the withdrawal of pharmaceutical
industry from many screening programs [127]. Besides, the analysis of
the increasing number of available genomes has led to the conclusion
that even though many natural products have been isolated over the
last decades, the majority of secondary metabolites is still undiscovered
[128]. Yet, the respective gene clusters responsible for their synthesis
are silent under common growth conditions, as they must be activated
by so far unknown environmental triggers [129,130]. Especially toxins,
whose synthesis is exclusively directed against the respective host organ-
ismor nutrition competitors, are strictly regulated to avoid detrimental or
self-destructive effects [11]. Since most natural proteasome inhibitors fall
into that category, this principlemaybe the rationale for the identiﬁcation
of novel compounds. In order to discover the correct environmental con-
ditions for their synthesis, it is necessary to screen extracts or secretions
by a robust, quick and unambiguous methodology on the presence of in-
hibitory substances. Once the trigger for biosynthesis is found, the down-
stream isolation and characterization of the small molecule is a
straightforward process relying on standard puriﬁcation techniques
(Fig. 3).Manymethods have been developed for assaying the proteasome
activity in vitro and in vivo, but they all actwithin certain principle bound-
aries (Table 1).
3. Chapter 2: Methods for proteasomal inhibitor detection
3.1. UV–VIS techniques
Themost popular and commonly applied proteasome assay uses un-
natural substrate peptides,which carry a C-terminal chromophor that is
internally quenched by the attachment to the peptide scaffold.
2-Naphtylamine (pNA) or 7-amino-4-methyl-coumarin (AMC) are the
most widespread and commercially available head groups, but also
4-methoxy-2-naphtylamine (MNA) has been described in literature
[131]. The primary sequence of the peptide tail determines the afﬁnity
for the appropriate substrate binding channel [132], thus allowing the
selective analysis of a single active site within the CP. The proteasomal
activities hydrolyze the chromophor, which then develops its absorp-
tive or ﬂuorogenic properties [133] (Fig. 3d). Hereby, the signal is
directly proportional to the enzymatic turnover, which makes the assay
suitable for quantitative measurements. The UV–VIS technique is
among the most applied methodologies in high-throughput-screenings
for compound identiﬁcation [134], but suffers from several severe draw-
backs that lead to high numbers of false positive and false negative re-
sults [11]. As the assay uses the UV–VIS spectrum of light, it is highly
susceptible to quenching and diffraction in suspensions or colorful solu-
tions, which are, however, typical for many microorganisms after
prolonged incubation periods [135–138]. Moreover, some organisms
produce ﬂuorogenic substances that mimic proteolytic activities
[129,139]. Hence, the background for this methodology is too high to
reliably measure inhibitor secretion in culture broth or other heteroge-
neous conglomerates [11,118,119].
3.2. Site speciﬁc activity probes (SSAP)
A more advanced approach has been developed that relies on the
irreversible interactions of a labeled ligand with the active sites of the
CP [13,133,140,141]. The inhibitory molecule, which has to equally
bind to all proteasomal active sites, is chemically linked to a ﬂuorescent
dye, e.g. DANSYL, rhodamine and BODIPY derivatives, and added to an
Fig. 3. Screening and isolation of natural CP inhibitors. a–c) By variation of the fermentation conditions, silent biosynthesis machineries can be switched-on, which can be detected
in automated high-throughput screens. Suitable environmental triggers are often deducible from the natural life-cycle of the respective organism. However, target-directed assays
that are based on the UV–VIS spectrum of light (d) often result in high numbers of false positives due to the intense color of fermentation media and organic extracts, which often
contain ﬂuorescent polyphenols and a whole array of pigments. Alternative techniques include the NMR approach (e, g) as well as the SSAP labeling of active subunits (f). Once the
triggering conditions are found, the downstream chromatographic puriﬁcation of the inhibiting compound (h) as well as its structure elucidation by mass spectrometry and
2D-NMR studies (i) are a straightforward process. The evaluation of cell permeability and the affection of distinct cellular pathways are accomplished by cytotoxicity measurements
(j) and substrate accumulation assays. The ﬁnal characterization of the compound in vitro is performed by IC50 measurements and co-crystallization with the CP (k–m).
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proteasomes [13,141–143]. The inhibitor moiety of the probe molecule
then covalently binds to the respective proteasomal sites, thereby
co-tagging them with the ﬂuorophore [133]. After submission to
SDS-PAGE, the three active β-subunits can be visualized in ﬂuorescence
gel scanning devices (Fig. 3f). Alternatively, cells can also be assessed by
confocalmicroscopy or ﬂow cytometry [144]. The assaywas initially de-
veloped to assess the cross reactivity of novel CP inhibitors, but it can
also be applied for the standard analysis of complex mixtures or
uncharacterized compounds [133,144]. The sample to be examined is
added to the proteasome before labeling it with the ﬂuorescent probe.
If it contains an inhibitory substance, the active sites are blocked before
the probe can bind, thus suppressing the labeling and in turn the signal
after SDS-PAGE development. This linear dependence results in a good
quantiﬁability of inhibition of all activities [141,144,145]. Moreover,
by using cells that co-produce several proteasome particle subtypes
such as lymphocytes, it is possible to determine selectivities for either
the cCP or the iCP in a competitive assay. However, the biggest advan-
tage of this method is its application in crude culture broth, since
disturbing chromogenic substances in the sample are removed during
gel electrophoresis. Furthermore, whole cells can be used in this assay
and therefore preparation of puriﬁed CP is not necessary [146]. The
method also allows co-evaluation of cell penetration of the inhibitory
compounds, thus making it a valuable alternative to immunological
methods [143]. Yet, the difﬁcult preparation of the probe, which must
be derived fromdeﬁned proteasome inhibitors synthesized beforehand,
is rather complicated and therefore the technique is restricted to only
advanced research laboratories with an attached organic chemistry de-
partment. Amajor drawback of the approach is that the probemolecule
has to react covalently and irreversibly with the respective subunit
[13,99] and eventually displaces all non-covalent CP inhibitors. Since
TMC-95A is the only non-covalent natural product identiﬁed to date
and due to the high expectations towards such compounds, this is a poi-
gnant disadvantage of the method.3.3. Ub accumulation assays
Contrary to the techniques described above, the UPS activity can also
be assessed on the level of the proteome. A straightforward approach
takes advantage of the accumulation of ubiquitinated proteins after
treatment of mammalian cells with inhibitory compounds [147]. After
lysing the cells and submission of the crude extract to SDS-PAGE,
ubiquitinated proteins can be visualized by western blot analysis
[147,148]. The assay is able to detect all kinds of cell-penetrating UPS
inhibitors and exclusively uses commercially available compounds,
thus making it an ideal methodology for broad applications. However,
the technique is rather indirect as it does neither primarily detect the
activity of the core particle, nor the digestion of an intracellular substrate,
but the accumulation of Ub labels. Their respective levels are determined
by the complex dependencies within the ubiquitination system and can
be inﬂuenced by a broad variety of mechanisms, e.g. stress response
reactions, deubiquitination or altered abundances of regulatory particles
[149–152]. Furthermore, the ultimate result is merely an ubiquitination
ﬁngerprint of the proteome, thus precluding any form of quantiﬁcation.
The approach is also neither speciﬁc for any proteasomal subunit, CP
type or even the whole UPS [153,154]. Plus, selective inhibition of only
one subunit does not necessarily lead to decreased degradation of sub-
strate proteins [55,155]. An additional disadvantage of this method is
its complicated performance and time consuming execution: Every cell
extract has to be standardized in its concentration, the blot has to be
co-stained against at least one housekeeping protein and the concentra-
tion of ubiquitinated proteins must differ considerably to get resolved in
the western blot analysis. To conclude, the approach is not suitable for
screenings but might support hit identiﬁcations to complement other
methodologies.3.4. Pathway speciﬁc accumulation assays
Similar to the Ubmonitoring technique, it is also possible to quantify
intracellular proteasome substrates [156–158]. The concentration levels
of short-lived proteins like cyclins or the tumor suppressor protein p53
are most affected by proteasome inhibition [15,159]. One of the ﬁrst as-
says using western blot analysis focuses on the NF-κB pathway [156].
The eponymous transcription factor is inactively sequestered in the cy-
tosol by binding to its inhibitory counterpart IκBα [72]. Upon cellular
stimulation by TNFα or IL-1, IκBα is phosphorylated and subsequently
submitted to UPS degradation [72]. The generated NF-κB protein enters
the nucleus and starts transcription of various, mostly inﬂammation re-
lated genes [160]. However, if the CP is blocked by a cell-penetrating in-
hibitor, IκBα accumulates and can be detected by semi-quantitative
immunoblotting analysis [156]. The method was initially designed for
evaluation of pathways that are disturbed by CP blockage, as well as
analysis of different tumor subtypes [161,162], but it can also be applied
for detection of inhibitors in culture medium. Contrary to the Ub accu-
mulation assay, it uses a distinct cellular and natural substrate of the
CP, thus making this direct approach less prone to disruptive factors.
Furthermore, its pathway speciﬁcity directly connects the target modu-
lation exerted by the inhibitors on the proteasome with a biological ef-
fect such as the down-regulation of inﬂammatory cyclins by the
shutdown of the immunoproteasomal activities [104,163]. The tech-
nique is suitable for detection of all kinds of CP inhibitors and in contrast
to the difﬁcult-to-access activity probe molecules, antibodies against
IκBα are commercially available. In agreement with the Ub monitoring
approach, this approach does neither distinguish between the different
subunits affected nor CP subtypes [11,164]. Thus, it can bemisleading in
that IκBαmay still be degradable by a CP that is selectively blocked only
in one activity [54]. Moreover, it is not speciﬁc towards the proteasome,
but may reﬂect inhibition of previous steps, for example ubiquitination
or phosphorylation of IκBα [165]. In addition, the execution of this assay
variant is time-consuming and the results can be ambiguous due to the
semi-quantitative character of western blot analyses.
3.5. Translational ﬂuorescent fusion substrates
Due to the difﬁcult performance of the substrate monitoring assays,
an alternative methodology has been developed using transfected cell
lines with stable expression of a fusion construct such as Ub–Luciferase
[166,167] or Ub-green ﬂuorescent protein (GFP) [155]. Although the re-
porter protein is not linked to Ub via an isopeptide bond, the fusion
protein is further ubiquitinated and subsequently degraded by the
proteasome. In order to prevent deubiquitination, the C-terminal gly-
cine residue of Ub is mutated to valine, thus inevitably leading to a lin-
ear degradation of the reporter protein by the UPS [155]. If the cells
are treatedwith culturemedium that containsUPS inhibitors, GFP accu-
mulates and can easily be quantitatively measured by either ﬂuores-
cence microscopy or spectrometry [155]. Once a suitable cell line is
established, the experiment can easily be transferred to any cell culture
facility. Detrimental effects by colorful or ﬂuorescent culture broths that
would affect the signal-to-noise ratio can be vastly eliminated by rins-
ing the cells before the measurement. However, this methodology
again lacks speciﬁcity towards the 20S proteasome, since alterations
of the RP functionality will lead to a positive assay result as well [153].
Additionally, the intracellular abundance of the 26S proteasome may
be submitted to ﬂuctuations caused by impaired assembly or feedback
regulations during treatment of the cells with culture broth [152]. The
approach is also neither speciﬁc for a particular proteasome particle
nor a single active subunit as the overall proteolytic activity ismeasured
[155,168–170]. In agreement with the substrate accumulation assays,
inhibition of one or even two proteasomal activities does not necessar-
ily lead to a signiﬁcantly reduced GFP degradation [54,171]. Finally, the
detection limits in cell culture based approaches are usually far higher
than in vitro, thus neglecting compounds that are produced only in
Table 1
Pros and cons of the presented methodologies in natural product screenings.
Methodology Advantages and disadvantages in natural product screenings for the CP
1) UV–VIS - Commercially available substrates
- Quantitative and linear readout
- Applicable for IC50 and kinetics
- Easy performance on fermentation screenings
- Monitoring of selected activities
- Unspeciﬁc in vivo
- Signal-to-noise ratio affected by quenching,
absorption and auto-ﬂuorescence
2) SSAP - Co-evaluation of cell permeability
- Subunit selectivity of distinct CP types
- Applicable for ﬂuorescent microscopy
- Quantiﬁable
- Reliability in crude conglomerates
- Sophisticated probe preparation
- Complex quantiﬁcation
- Comprehensive UPS analysis impossible
- Detection of reversible inhibitors impossible
3) Ub accumulation - Commercially available
- Co-evaluation of cell permeability
- Analysis of the whole UPS
- Insensitive readout
- Unspeciﬁc




4) Pathway speciﬁc accumulation - Commercially available
- Co-evaluation of cell permeability
- Pathway affection in various cell lines
- Analysis of cellular function
- Direct assay
- Complex handling and improper quantiﬁcation
- Ambiguous results
- False-negative on selective inhibition




- Easy readout and quantiﬁability
- Co-evaluation of cell permeability
- Sensitive of detection
- Applicable in FACS and ﬂuorescent microscopy
- Reliability in crude conglomerates
- Lack of proteasome speciﬁcity
- False-negative on selective inhibition
- Off-target effects
6) NMR spectroscopy - Native proteasomal substrate
- Easy peptide synthesis
- Reliability in crude conglomerates
- Applicable in high-throughput-screenings
- High sensitivity
- Subunit speciﬁc, quantiﬁable, unambiguous readout
- Substrate amount
- Restricted to in vitro analysis
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substances.
3.6. NMR spectroscopy mining for CP inhibitors in conglomerates
Recently an orthogonal methodology was established to directly
measure the proteolytic activity exerted by the CP [11]. Contrary to pre-
viously described techniques, it is not based on UV–VIS but on NMR
signal detection and is therefore not affected by any diffraction or
quenching effects in crudemixtures. The assay uses a native proteasomal
peptide substrate,which is derived from the digestion pattern of themu-
rine JAK-1 kinase [54]. Labeling of the peptide probe, which can be gen-
erated by standard peptide chemistry in high amounts, occurs at the
scissile peptide bond with a 13C-carbonyl carbon [11]. Upon hydrolysis,
a distinct shift is observed in the high ﬁeld area of the recorded NMR
spectrum that is assigned to the altered chemical environment of the
13C-probe in the free carbonic acid product versus the bound amide
educt [11] (Fig. 3e, g). Although other substances in a given sample
also give rise to the NMR signals, most of them are in the range of 0 to
150 ppm,whereas the probe atom is detected at 170 ppm. Furthermore,
as the abundance of the 13C probe is 100% versus 1.1% in natural com-
pounds, the signal-to-noise ratio is abundantly increased [11]. Similar
to conventional ﬂuorogenic peptide assays, the sequence of the peptide
can be adapted towards a deﬁned CP activity, thus allowing to selectively
measure inhibition of a distinct active site [132]. Therefore, it might be a
rather simple approach to alter the primary sequence to produce speciﬁc
substrate molecules for the ChTL, TL and CL activities, thus allowing si-
multaneous measurement of all proteolytic centers at once [132,172].
Furthermore, the assay is able to detect covalent, non-covalent, revers-
ible and irreversible inhibitors. However, a drawback of the method is
the large amount of peptide substrates, which have to be used inmillimolar concentrations, as the sensitivity of recorded NMR spectra
in general lacks far behind ﬂuorescence approaches. On the other
hand, the technique is suitable for screening of a vast number of samples,
as the processing of one assay can be accomplished within 15 min on a
500-MHz NMR spectrometer [11]. Therefore the NMR assay still allows
the performance of a standard amount of approximately 100 samples
of crude extracts or conglomerates containing thousands of different
compounds per day. Plus, the results yielded by this assay are unambig-
uous. The introduction and a proof of principle of this recently developed
methodology were reported for the insect pathogenic bacterium
Photorhabdus luminescens [11], which was suspected to produce a
proteasome inhibitor at a deﬁned state during its pathogenic life-cycle
[12,173].
4. Chapter 3: Application of proteasome assays for natural product
mining on syrbactins
4.1. Triggering secretion of natural CP inhibitors during deﬁned life stages
All assays described in chapter 2 are valuable tools for the detec-
tion of proteasome inhibiting substances in extracts and crude culture
broths of microorganisms, plants or fungi. Furthermore, they can be
used to screen different fermentations in order to initiate the biosyn-
thesis of secondary metabolites that are silenced under common
growth conditions [174]. Matching environmental triggers can often
be inferred from the natural life stages of the respective organisms
and the objective for which the compound is produced. In the ﬁeld
of CP inhibitors, the ﬁrst substance to which a biological role could
be assigned was the syrbactin compound SylA (Fig. 2h) [12]. It is pro-
duced by the phytopathogenic bacterium Pseudomonas syringae,
which causes the brown spot disease in bean plants and other
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cluster responsible for the synthesis of SylA, the infectivity of
P. syringae towards the host organism was decreased by 70%, thus
highlighting the role of the CP inhibitor as a virulence factor [12]. In-
terestingly, the compound is secreted by the bacterium only under
speciﬁc growth conditions that simulate the chemical composition
of plant leaves by the addition of fructose and phenolic sugars
[80,177]. This ﬁnding corresponds to the general secretion pattern
of many toxic compounds that are only produced after their initiation
by environmental conditions resembling those in the corresponding
host organism, thus ensuring a directed and selective application.
Subsequent to the discovery of SylA, a similar substance namedGlbA
(Fig. 2i) was identiﬁed in a database search and determined to be a
proteasome inhibitor as well [12,81]. Its characterization revealed that
GlbA was the strongest CP inhibitor among all previously described
compounds with extraordinary properties in cell culture experiments
[12]. These results fuelled the search for further members of the
syrbactin family. The disclosure of the genes responsible for the synthe-
sis of SylA and GlbA led to the identiﬁcation of many species with
similar clusters among the genera Burkholderia and Photorhabdus,
which intriguingly both comprise human pathogenic organisms like
P. asymbiotica, B. pseudomallei or B. mallei [178,179]. Curiously, the ge-
netic analysis also led to the conclusion that B. mallei is probably not
able to produce the corresponding proteasome inhibitor because it
carries a transposon mediated intron in the decisive gene cluster
[178]. Notably, B. mallei displays a signiﬁcantly reduced pathogenicity
compared with B. pseudomallei, which even has been classiﬁed as
weapon of mass destruction [180]. This ﬁnding again alludes to the bi-
ological role of CP inhibiting compounds as virulence factors.
In order to discover and characterize the effector molecules pro-
duced by the identiﬁed organisms on a chemical level, extensive studies
were carried out to ﬁnd suitable fermentation procedures for the induc-
tion of the respective biosynthetic machineries [11,118]. As shown for
the insect pathogen Photorhabdus luminescens, the combination of
different methodologies was investigated on the biosynthesis of a
syrbactin-like compound [11]. Distinct growth media of the bacteria
were initially monitored by common ﬂuorescence and UV–VIS based
methods. Yet, due to the autoﬂuorescence and the intensive color of
Photorhabdus cultures, which range from light blue to dark shades of
red (Fig. 3a), the results were too ambiguous to infer the presence of
an inhibitory compound [11,133]. Contrary to the UV–VISmethodology,
the implementation of the NMR technique for the screening of culture
conditions yielded unambiguous results (Fig. 3e, g). Surprisingly, the
performed experiments revealed the absence of any CP modulating
compound, hence proving that the corresponding biosynthetic machin-
ery is silent under standard growth conditions [11,181]. Therefore,
Photorhabdus was hypothesized to require an equivalent molecular
trigger as Pseudomonas syringae to induce its virulent phase and in
consequence the production of the predicted proteasome inhibitor.
Screening of deﬁned media with various additives ﬁnally disclosed
the prerequisite to trigger inhibitor biosynthesis in Photorhabdus [11].
In a low osmolarity medium, which was inoculated by a saturated
Photorhabdus culture cultivated at high sodium chloride concentrations,
the bacteria instantly started to secrete a powerful inhibitory compound,
whichwas detectable by the NMR assay within few hours after the envi-
ronmental change. Upon addition of conditioned and induced medium
to an assay mixture containing puriﬁed yeast proteasome and labeled
peptide, the digestion of the substrate was prevented as displayed by
the 13C NMR spectra [11] (Fig. 3g).
4.2. Biological background of sensory systems exempliﬁed
on P. luminescens
Similar to P. syringae, this switch from the quiescent to the patho-
genic phase after the transfer to an inducing medium reﬂects the bi-
polar life-cycle of the entomopathogenic bacterium. During the ﬁrstlife stage of Photorhabdus, the bacteria hibernate in the gut of their
symbiont nematode Heterorhabditis, which searches the soil for insect
larvae [182,183]. When the worm detects its prey, it penetrates the
insect to reach the hemocoel, where it regurgitates the bacteria. To-
gether, they kill the larvae in a concerted action and feed on the tissue
to start reproduction. Once the carcass is exploited, the nematodes
devour the bacteria, and both organisms leave the larvae to search
for a new prey [183]. During its virulent phase, Photorhabdus pro-
duces a plentitude of bioactive molecules to kill the insect and to
protect it against other scavenging organisms [184]. This is reﬂected
by the observation that Photorhabdus occurs in two distinct phases
in vitro [173]. Whereas it is non-infective in phase I, it develops full
activity and biosynthesis of various secondary metabolites in phase
II [12,182]. The induction of the pathogenic phase and in turn the
secretion of the CP inhibitor was shown to be strictly controlled in
Photorhabdus and must be induced by the identiﬁed environmental
conditions [11,181]. Besides, the compound cannot be detected
under the growth conditions for SylA biosynthesis in P. syringae or
GlbA production in the respective Burkholderiales strain K481-B101
[11]. This demonstrates the adaptation of the systems of these bacte-
ria to their respective host organisms. Furthermore, the involvement
of a proteasome inhibitor in a symbiotic relationship has not been ob-
served before. The bacterium presumably suspends its biosynthesis
until it is released into the insect larvae. Photorhabdus then has to
safeguard and foster the second generation of nematodes by the se-
lective application of its toxins [11,182].
After the establishment of the induction procedure, Stein et al. dem-
onstrated the straightforward downstream processing of the inhibiting
substance by its isolation and identiﬁcation as CepI [11,82] (Fig. 3h–i).
Surprisingly, the molecular structure matches GlbA except from one
methyl moiety at the distal terminus from the Michael-system that
binds covalently to the active proteasomal subunits (Figs. 2h–j, 3m).
This was unexpected, as the gene clusters between the organisms
share only moderate sequence homology. Therefore the high overall
similarity of the small molecules was unforeseen, which illustrates the
unpredictability of a secondary metabolite on the basis of the primary
DNA sequence. In contrast to the inhibitory compounds, the sensory
systems diverge signiﬁcantly because they are optimized towards the
circumstances during the respective life-cycles of the producing mi-
crobes. Thus, also virulence factors that are not primarily directed
against humans are suitable for development of novel pharmaceutical
compounds because their lead structures are not altered between the
targeted organisms.
However, the characterization of CepI determined the compound
to range among the most potent proteasome inhibitors described so
far [11]. While its isolation was achieved by the application of the
NMR assay, the in vivo characterization of CepI was performed by
cell viability assays and the NF-κB analysis [11] (Fig. 3j), thereby ver-
ifying its cell penetration and the affection of the UPS. The crystal
structure analysis revealed that the increased hydrophobic surface is
crucial for the enhanced binding properties of CepI compared with
GlbA [11] (Fig. 3k–m). Yet, the prediction of the extent of this effect
is deﬁnitely not possible by computational methods to date. Since
also mammalian pathogenic organisms have been identiﬁed with
gene clusters similar to those in P. luminescens [12,178] future analy-
sis will show whether they are capable to produce analogous com-
pounds with optimized inhibitory properties for the human cCP, iCP
or tCP.
5. Conclusions
The UPS is a key player in crucial cellular processes [1]. Its
dysregulation is closely linked to various malignancies including can-
cer and autoimmune diseases [6]. In contrast to this vast applicative
scope of UPS modulating agents, the CP inhibitor bortezomib is only
approved for treatment of the blood cancers multiple myeloma and
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ity of the boronic acid inhibitor, which considerably deteriorates its
pharmacokinetic effects e.g. in treatment of solid tumors [91]. The de-
velopment and release of second generation therapeutic agents now
announce the implementation of more speciﬁc and less reactive com-
pounds with broader applications in this important ﬁeld of research
[6]. Yet, the broad range of possible medical indications, as well as
primary and secondary resistances in cancer therapy, fuels the search
for novel UPS and especially CP modulating compounds. A huge spec-
trum of substances acting on the proteasome has been identiﬁed al-
ready, thus making the discovery of other compound classes most
likely [83,185]. Albeit, natural product research stagnates or is even
reduced in pharmaceutical industry in our days, the lead structures
derived from these substances remain a central focus due to their en-
hanced pharmacological properties [10]. Although genome analyses
have demonstrated that only a minor share of compounds produced
by the sequenced organisms has been isolated to date, the majority
is inaccessible by common isolation procedures because biosynthesis
only occurs under distinct environmental conditions that reﬂect the
cognate life stages of the analyzed species [11]. However, these com-
pounds belong to the most fascinating group of natural compounds
since they often serve as molecular keys to the initiation of important
cellular processes such as immune response modulation in a host or-
ganism. Therefore, the disclosure of suitable molecular triggers to ini-
tiate the change of life stages is a promising means to expand the
limits of natural compounds research [10].
Yet, in order to detect the right environmental circumstances, suit-
able methods for the assessment of compound production in crude
culture broth or raw extracts must be available. In the case of the CP,
several approaches have been developed and are comparatively
presented in this review. Although UV–VIS and ﬂuorescent techniques
using unnatural peptide substrates are very popular and easy to per-
form, they bear disadvantages and are error prone in complexmixtures.
More advancedmethods have been deceived in vitro and in vivo that ac-
count for these drawbacks that, however, also hold speciﬁc disadvan-
tages according to their nature. Cell based techniques for example,
suffer from their lack of selectivity for the UPS, the crosstalk between
several pathways and a difﬁcult performance. On the other hand, they
are suitable to co-assess the cell penetration or even the affection of a
distinct pathway by a given compound [161]. Hence these methods
have a limited application for high-throughput approaches but are es-
sential in the characterization of an isolated compound. Contrarily,
SSAP based methods are suitable to address the intracellular affection
of the CP by a straightforward and direct approach [142], but they re-
quire the synthesis of a radioactively or ﬂuorescent labeled proteasome
inhibitors, which are challenging to obtain. A new promising technolo-
gy represents the recently developed NMR technique [11], which com-
bines the advantage of a direct, speciﬁc and robust assay with excellent
detection limits and a good applicability for high-throughput screenings
of conglomerates, culture broths and cell extracts. Its successful applica-
tionwas instantly demonstratedwith the isolation and characterization
of CepI, one of the strongest proteasome inhibitors identiﬁed to date,
thus demonstrating the vast potential of the approach. However, it is
the combination of different methods with their respective pros and
cons and their varying kinds of information (Table 1) that must be ap-
plied to expand the spectrum of natural proteasome inhibitors during
the next decade.References
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